{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:52:03Z","timestamp":1761238323026},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T00:00:00Z","timestamp":1472083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0161826","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T17:41:43Z","timestamp":1472146903000},"page":"e0161826","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of IVIG Formulation on IgG Binding to Self- and Exo- Antigens In Vitro and In Vivo"],"prefix":"10.1371","volume":"11","author":[{"given":"Susann","family":"Cattepoel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Gaida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Kropf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc W.","family":"Nolte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Bolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia M.","family":"Miescher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,8,25]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10875-008-9231-2","article-title":"Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies","volume":"29","author":"MR Stein","year":"2009","journal-title":"J Clin Immunol"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.autrev.2012.02.006","article-title":"Intravenous immunoglobulin: exploiting the potential of natural antibodies","volume":"11","author":"SV Kaveri","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"Suppl 1","key":"ref3","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1007\/s10875-010-9413-6","article-title":"Anti-amyloidogenic activity of IgGs contained in normal plasma","volume":"30","author":"B O'Nuallain","year":"2010","journal-title":"J Clin Immunol"},{"issue":"Suppl 1","key":"ref4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2249.2009.04026.x","article-title":"Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation","volume":"158","author":"R Schwartz-Albiez","year":"2009","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.iac.2008.06.004","article-title":"History of immunoglobulin replacement","volume":"28","author":"MM Eibl","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"issue":"6","key":"ref6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/08916930902785363","article-title":"Intravenous immunoglobulin therapy for autoimmune diseases","volume":"42","author":"Y Arnson","year":"2009","journal-title":"Autoimmunity"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"MD Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.immunol.26.021607.090232","article-title":"Anti-inflammatory actions of intravenous immunoglobulin","volume":"26","author":"F Nimmerjahn","year":"2008","journal-title":"AnnuRev Immunol"},{"issue":"7","key":"ref9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.it.2009.03.011","article-title":"Immune therapy for age-related diseases","volume":"30","author":"ME Weksler","year":"2009","journal-title":"Trends Immunol"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.10253","article-title":"Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer&apos;s disease","volume":"52","author":"R Dodel","year":"2002","journal-title":"Ann Neurol"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.intimp.2009.10.005","article-title":"Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations","volume":"10","author":"AC Klaver","year":"2010","journal-title":"Int Immunopharmacol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1742-2094-8-93","article-title":"ELISA measurement of specific non-antigen-bound antibodies to Abeta1-42 monomer and soluble oligomers in sera from Alzheimer&apos;s disease, mild cognitively impaired, and noncognitively impaired subjects","volume":"8","author":"AC Klaver","year":"2011","journal-title":"J Neuroinflammation"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3233\/JAD-2010-1353","article-title":"Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta","volume":"20","author":"K Balakrishnan","year":"2010","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1212\/WNL.0b013e3181ae7aaf","article-title":"IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders","volume":"73","author":"H Fillit","year":"2009","journal-title":"Neurology"},{"issue":"1\u20132","key":"ref15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jneuroim.2010.06.010","article-title":"Measurement of anti-beta amyloid antibodies in human blood","volume":"227","author":"P Szabo","year":"2010","journal-title":"J Neuroimmunol"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jneumeth.2010.01.018","article-title":"Measurement of anti-Abeta1-42 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding","volume":"187","author":"AC Klaver","year":"2010","journal-title":"J Neurosci Methods"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbrc.2010.06.073","article-title":"Heterogeneous antigen recognition behavior of induced polyspecific antibodies","volume":"398","author":"JD Dimitrov","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ab.2011.07.007","article-title":"Important parameters for evaluation of antibody avidity by immunosorbent assay","volume":"418","author":"JD Dimitrov","year":"2011","journal-title":"Anal Biochem"},{"issue":"14","key":"ref19","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1111\/j.1742-4658.2010.07714.x","article-title":"Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis","volume":"277","author":"IK Djoumerska-Alexieva","year":"2010","journal-title":"FEBS J"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"e63162","DOI":"10.1371\/journal.pone.0063162","article-title":"Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro","volume":"8","author":"S Cattepoel","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1471-4159.2001.00592.x","article-title":"Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies","volume":"79","author":"MP Lambert","year":"2001","journal-title":"J Neurochem"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1021\/bi047982v","article-title":"Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer&apos;s disease","volume":"44","author":"MR Reynolds","year":"2005","journal-title":"Biochemistry"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ab.2008.03.035","article-title":"Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet","volume":"377","author":"Y Abdiche","year":"2008","journal-title":"Anal Biochem"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/jnr.490310405","article-title":"An immortalized cell line expresses properties of activated microglial cells","volume":"31","author":"V Bocchini","year":"1992","journal-title":"J Neurosci Res"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.4049\/jimmunol.166.12.7496","article-title":"Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q","volume":"166","author":"SD Webster","year":"2001","journal-title":"J Immunol"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1586\/eci.11.97","article-title":"Safety of L-proline as a stabilizer for immunoglobulin products","volume":"8","author":"JB Hagan","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2217\/imt.10.108","article-title":"L-proline-stabilized human IgG: Privigen(R) 10% for intravenous use and Hizentra(R) 20% for subcutaneous use","volume":"3","author":"M Berger","year":"2011","journal-title":"Immunotherapy"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMcibr0803649","article-title":"The antiinflammatory IgG","volume":"359","author":"SV Kaveri","year":"2008","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1196\/annals.1423.071","article-title":"Self-reactivity in the dimeric intravenous immunoglobulin fraction","volume":"1110","author":"A Schaub","year":"2007","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.biologicals.2009.09.002","article-title":"L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions","volume":"38","author":"R Bolli","year":"2010","journal-title":"Biologicals"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0161826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T00:51:35Z","timestamp":1588985495000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0161826"}},"subtitle":[],"editor":[{"given":"Josef","family":"Priller","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,25]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0161826","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,25]]}}}